Achieving an Optimal Outcome in the Treatment of Infections
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 37 (1), 1-16
- https://doi.org/10.2165/00003088-199937010-00001
Abstract
Over the past few decades, the importance of applying pharmacokinetic principles to the design of drug regimens has been increasingly recognised by clinicians. From the perspective of antimicrobial chemotherapy, an improvement in clinical outcome and/or a reduction in toxicity are of primary interest. Before application of these pharmacokinetic theories can be effective, the interrelationships between antimicrobial, pathogen and host factors must be clearly defined. Information regarding the pharmacokinetics of the antimicrobial and the quantification of pathogen susceptibility is required. Even though susceptibility end-points such as minimum inhibitory concentration (MIC) and minimum bactericidal concentration are widely employed, they do not provide any information on dynamic changes of bacterial densities. In this regard, time-kill studies can provide more basic knowledge of the complex bacterial responses to the antimicrobial. Better prediction of these responses can be afforded by the use of mathematical models. More recently, various surrogate end-points employing a combination of suitable pharmacokinetic parameters and susceptibility data, for example the ratio of peak concentration to MIC, the area under the concentration-time curve above the MIC (AUC>mic ), the time above the MIC, or the area under the inhibitory curve (AUIC), have been suggested for better prediction of the activity of different classes of antimicrobials. To allow more extensive investigations of the contribution of pharmacokinetics to the pharmacodynamics of antimicrobials, various in vitro kinetic models have been developed. However, certain limitations exist, and it is necessary to avoid over-interpretation of the data generated by these models. Two important microbial dynamic responses, postantibiotic effect and resistance selection, must be further explored before the full impact of pharmacokinetics on antimicrobial chemotherapy can be depicted. The present paper aims at discussing all the relevant factors and provides some pertinent information on the use of pharmacokinetic-pharmacodynamic principles in antimicrobial therapy.Keywords
This publication has 71 references indexed in Scilit:
- Antimicrobial resistance issues of the futureDiagnostic Microbiology and Infectious Disease, 1996
- The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to OutcomeClinical Pharmacokinetics, 1995
- Pharmacodynamic Modeling of Bacterial Kinetics: β‐Lactam Antibiotics against Escherichia coljJournal of Pharmaceutical Sciences, 1994
- Impact of Dosage Regimens on the Efficacy of Piperacillin Against Pseudomonas Aeruginosa in Neutropenic MiceJournal of Pharmaceutical Sciences, 1988
- Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosaJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Chromosomal -lactamase expression and antibiotic resistance in Enterobacter cloacaeJournal of Medical Microbiology, 1988
- In Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic MiceThe Journal of Infectious Diseases, 1988
- Microbial Kinetics of β-Lactam Antibiotics Against Escherichia coliJournal of Pharmaceutical Sciences, 1984
- Kinetic Analysis and Characterization of the Bacterial Regrowth after Treatment of Escherichia coli with β-Lactam AntibioticsJournal of Pharmaceutical Sciences, 1984
- Kinetics and mechanisms of action of drugs on microorganisms VII Quantitative adherence of sulfonamide action on microbial growth to a receptor-site modelJournal of Pharmaceutical Sciences, 1967